ANIMATUS BIOSCIENCES
Animatus Biosciences is redefining regenerative medicine with innovative technology focused on heart failure treatment. They develop synthetic mRNA platform-based therapeutics aimed at regenerating cardiac tissue, addressing the lack of effective treatments for reversing heart failure, which affects millions worldwide. Their mission is to enable the regeneration of heart and other tissues through advanced gene network control and synthetic factors.
Industries
Nr. of Employees
small (1-50)
ANIMATUS BIOSCIENCES
Patents
Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts
US-11744902-B2
View Details
Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts
US-11744902-B2
View DetailsProducts
Modified mRNA therapeutic candidate for cardiac regeneration
A combination of chemically modified mRNAs encoding engineered transcriptional regulators designed to induce cardiomyocyte cell-cycle entry, reduce infarct size, and restore cardiac function in preclinical models when delivered via intramyocardial injection.
Modified mRNA therapeutic candidate for cardiac regeneration
A combination of chemically modified mRNAs encoding engineered transcriptional regulators designed to induce cardiomyocyte cell-cycle entry, reduce infarct size, and restore cardiac function in preclinical models when delivered via intramyocardial injection.
Expertise Areas
- mRNA therapeutics development
- Cardiac regenerative medicine
- Preclinical cardiovascular models (mouse myocardial infarction)
- Stem cell engineering and expansion
Key Technologies
- Modified/chemically modified mRNA therapeutics
- Engineered transcription factor mRNAs (SRF/YAP variants)
- Intramyocardial catheter delivery
- Rotating suspension / rotary cell culture bioreactors
News & Updates
Animatus Biosciences was selected to participate in the MassChallenge Texas in Houston 2019 accelerator program, gaining access to a global network, mentoring, programming, co-working space, and corporate partners.
Dr. Schwartz, Chief Scientific Officer, will present at the summit, highlighting the company's advancements in mRNA technology.
A press release discussing the potential of Animatus's regenerative mRNA technology for heart repair.
Research papers reporting the impact of YAP-5SA and STEMIN mRNA in mouse heart regeneration, published in The Journal of Cardiovascular Aging, with over 15,000 views.
Animatus Biosciences was selected to participate in the MassChallenge Texas in Houston 2019 accelerator program, gaining access to a global network, mentoring, programming, co-working space, and corporate partners.
Dr. Schwartz, Chief Scientific Officer, will present at the summit, highlighting the company's advancements in mRNA technology.
A press release discussing the potential of Animatus's regenerative mRNA technology for heart repair.
Research papers reporting the impact of YAP-5SA and STEMIN mRNA in mouse heart regeneration, published in The Journal of Cardiovascular Aging, with over 15,000 views.